Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial.

J. Randolph Hecht,Yung-Jue Bang,Shukui Qin,Hyun-Chul Chung,Jianming Xu,Joon Oh Park,Krzysztof Jeziorski,Yaroslav Shparyk,Paulo M. Hoff,A. Sobrero,Pamela Salman,Jin Li,Svetlana Protsenko,Marc Buyse,Karen Afenjar,Tomomi Kaneko,Allison Kemner,Sergio Santillana,Michael F. Press,Dennis J. Slamon

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial.

2017

LBA4001 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Keywords:

Clinical Oncology
Capecitabine
Oxaliplatin
Oncology
Lapatinib
Adenocarcinoma
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations